SMW Free Realtime Trade Alerts -- Our Last 2 Trade Alerts were VII and NFEC, easy 40-75% wins in minutes, Join Today for FREE!!

GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
GWPH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Loading GWPH News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.79%23.033.5%$613.45m
SHPGShire PLC Sponsored ADR
0.68%193.600.4%$309.09m
PRGOPerrigo Co. Plc
-1.92%90.743.1%$177.53m
RLYPRelypsa, Inc.
-0.13%31.9327.7%$161.27m
ENDPEndo International Plc
-2.09%17.345.6%$129.72m
ICPTIntercept Pharmaceuticals, Inc.
0.69%159.5912.8%$88.66m
JAZZJazz Pharmaceuticals Plc
-1.71%138.923.1%$84.62m
MNKMallinckrodt Plc
0.09%66.879.0%$82.93m
HZNPHorizon Pharma plc
1.98%19.1011.8%$64.83m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.03%93.177.7%$64.80m
UTHRUnited Therapeutics Corporation
0.29%112.4515.4%$60.77m
SAGESAGE Therapeutics, Inc.
1.42%44.338.4%$60.07m
ALRAlere Inc.
0.34%44.074.6%$46.50m
MDCOMedicines Company
0.14%35.4319.2%$36.67m
ICLRICON Plc
4.70%74.564.6%$36.24m

Company Profile

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and Pipeline Research & Development. The Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.